Day Zero Diagnostics Doubles Down on epiXact® Service for Investigating Healthcare-Associated Infection Outbreaks Supported by New NIH Funding Award
Dec 09, 2020•over 4 years ago
Description
Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced it has received a Phase I Small Business Innovation Research (SBIR) award from the National Institute of Allergies and Infectious Disease (NIAID) of the National Institutes of Health (NIH).